// App-Quantinova.ai

PB1702 : EFFICACY AND SAFETY OF LUSPATERCEPT VERSUS PLACEBO IN PATIENTS WITH MYELOPROLIFERATIVE NEOPLASM-ASSOCIATED MYELOFIBROSIS ON JAK2 INHIBITOR THERAPY AND REQUIRING RBC TRANSFUSIONS (INDEPENDENCE TRIAL)

Researchers

Presenter

  • Ruben Mesa

Principal Investigators

  • Giovanni Barosi

  • Claire Harrison

  • Jean-Jacques Kiladjian

  • Srdan Verstovsek

  • Torsten G. Gerike

  • Vincent Chia

  • Jeevan K. Shetty

  • Yue Wang

  • Heidi Marks

  • Francesco Passamonti

Medical Centers

  • Mays Cancer Institute at UT Health San Antonio MD Anderson,San Antonio,United States

  • Policlinico S. Matteo Foundation, Pavia, Italy

  • Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX, Houston, TX

  • Bristol Myers Squibb, Princeton, New Jersey, United States

  • Department of Medicine and Surgery, University of Insubria, Varese, Italy

  • Hopital Saint-Louis and Universite Paris Diderot, Paris, France

  • Guy's And St Thomas NHS Foundation Trust, London, United Kingdom

  • Celgene International Sàrl, a Bristol Myers Squibb Company, Boudry, Switzerland

Locations

  • United States

  • Italy

  • France

  • United Kingdom

  • Switzerland

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Blood/haematological Diseases

Disease

  • Myeloid neoplasms

  • Essential thrombocythemia

  • Myelofibrosis

  • Anemia

Biomarkers

  • Red Blood Cells

Drug/Treatment

  • Pomalidomide

  • CC-4047

  • luspatercept

  • Hydroxyurea

  • Thalidomide

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Multinational

Phase

  • III

Study Id's

  • NCT03194542

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved